New hope for rare liver disease: drug aims to slow damage

NCT ID NCT07216235

Recruiting now Disease control Sponsor: Zydus Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This long-term study tests whether saroglitazar magnesium can prevent serious liver complications in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo. The goal is to see if the drug delays events like liver failure, need for transplant, or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: saroglitazar magnesium
What this could lead to: If it works, this could provide a new treatment option to slow liver damage and delay serious complications in people with primary biliary cholangitis.
What could go wrong: This is an early-stage Phase 3 trial with 386 participants, so results may not apply to everyone. The drug may not outperform placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS

Contacts and locations

Locations

Zydus US101
RECRUITING

Indianapolis, Indiana, 46202, United States
Zydus US104
RECRUITING

Marietta, Georgia, 30060, United States
Zydus US105
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.